Innoviva (INVA) EPS (Weighted Average and Diluted): 2010-2025
Historic EPS (Weighted Average and Diluted) for Innoviva (INVA) over the last 14 years, with Sep 2025 value amounting to $1.08.
- Innoviva's EPS (Weighted Average and Diluted) rose 5300.00% to $1.08 in Q3 2025 from the same period last year, while for Sep 2025 it was $1.13, marking a year-over-year increase of 24.18%. This contributed to the annual value of $0.36 for FY2024, which is 83.64% down from last year.
- According to the latest figures from Q3 2025, Innoviva's EPS (Weighted Average and Diluted) is $1.08, which was up 40.26% from $0.77 recorded in Q2 2025.
- Innoviva's 5-year EPS (Weighted Average and Diluted) high stood at $2.80 for Q3 2022, and its period low was -$0.74 during Q1 2025.
- In the last 3 years, Innoviva's EPS (Weighted Average and Diluted) had a median value of $0.42 in 2023 and averaged $0.27.
- Its EPS (Weighted Average and Diluted) has fluctuated over the past 5 years, first plummeted by 2,850.00% in 2024, then spiked by 5,300.00% in 2025.
- Innoviva's EPS (Weighted Average and Diluted) (Quarterly) stood at $0.90 in 2021, then skyrocketed by 211.11% to $2.80 in 2022, then slumped by 65.00% to $0.98 in 2023, then slumped by 97.96% to $0.02 in 2024, then spiked by 5,300.00% to $1.08 in 2025.
- Its EPS (Weighted Average and Diluted) stands at $1.08 for Q3 2025, versus $0.77 for Q2 2025 and -$0.74 for Q1 2025.